Business
Kymera Therapeutics to Host Virtual R&D Day on December 16, 2021
WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET. Kymera’s R&D Day will include presentations from Nello Mainolfi, PhD, Co-Founder, President and CEO; Jared Gollob, MD, Chief Medical Officer; and other members of Kymera’s senior R&D management team. The event will provide a comprehensive update on Kymera’s lead programs and discovery pipeline and platform, including Key Multiple Ascending Dose (MAD) data from the KT-474 Phase 1 trialUpdates on IRAKIMiD (KT-413) and STAT3 (KT-333) programsPresentations on new pathways/programs approaching clinical developmentDeep-dive into platform capabilities, progress and its expansionOutline of the company’s vision and goals for the next 5 years A live webcast of the event, as well as a replay, will be available at: https://investors.kymeratx.com/RD-Day About Kymera TherapeuticsKymera Therapeutics (Nasdaq: KMYR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera’s Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera’s initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera’s goal is to be a global, fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has...